Regarding therapeutic implications, BTLA inhibition, in vitro, in combination with PD-1 and TIM-3 blockade reactivated dysfunctional melanoma antigen-specific CD8+T-cells, enhancing their proliferation and cytokine secretion [223]. Here, HAVCR2 is linked to melanoma.